• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers  

Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers  

Visualization Producer: Daniel Menzin

 

 

 

Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers

Curators: Daniel Menzin, Bsc (exp. 5/2021) and Aviva Lev-Ari, PhD, RN

  • Daniel Menzin: Application Developer in Tweepy and Python: Computerized Data Extraction and Analysis
  • Aviva Lev-Ari: Curator of the following manually extracted data sets in collaboration with:

 

  1. Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
  2. LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
  3. Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950 by Alex Crystal and Aviva Lev-Ari
  4. MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
  5. Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
  6. Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
  7. REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI by Stephen J Williams, PhD
  8. For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
  9. The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation
  10. e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views=Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW by Stephen J Williams and Aviva Lev-Ari

 

Comparative Analysis of Followers and The Followers of these two Handles’ Followers: Computerized Data Extraction and Data Analysis

  • @pharma_BI (LPBI Group’s Official) and
  • @AVIVA1950 (LPBI Group’s Founder’s Personal)

Results to be presented by Daniel Menzin on June 16, 2020 at LPBI Group’s Monthly Meeting with External Relations

Having the performed the Computerized Data Extraction on these two handles, it allows LPBI Group to calculate the following measures for our Twitter activities:

1. Summation for each variable = Total Followers per Account and Total for both Accounts

2. Summation for Total Followers’ Followers per Account and Total for both Accounts

3. Calculation of Ratios per Account

3.1 Institutional/total = xx%

3.2 Persons/Total= yy%

3.3 Media/Institutions / Total = zz%

4. Per Account – Segmentation of # Followers

4.1 per Total

4.2 per All Institutions

4.3 per All Persons

4.4 per Media Followers

5. Based on Bio – Manually I will place a start on the 521 Bios, these are “LPBI is Honored to be Followed by”

• They are TARGETED for a narrowcast message to each about

5.1 LPBI proposing to Follow the Journal,

5.2 List of Categories of Research (# articles in Journal’s archive available for download for $30 each)

5.3 Link to our Books, Title Orice Link to each book on Amazon

5.4 List of e-Proceedings LPBI has for download for $100 per Conference

5.5 List of Tweet Collection for Conference LPBI has for download for $100 per event’s Tweet Collection

6. All Media Followers

Targeted for Narrow casting Message

6.1 LPBI’s Portfolio of products

6.2 LPBI request for exploration of Partnership and Collaboration

7. Statistical Analysis

– 2 Bar Diagrams for each Handle one next to the other for all Total and for % above

– line diagrams

– pie diagrams

8. Narrow Casting messages

  • A.  @pharma_BI

a.1 Lists of Institution Followers targeted for Portfolio of Products

a.2 Media Institution targeted for Partnership

a.3 Persons – Proposal to follow the Website

a.4 Persons – Proposal to Publish in the Journal as Guest Author

  • B. @AVIVA1950 – List of Institution Followers targeted for

b.1 = a.1

b.2 = a.2

b.3 = a.3

b.4 = a.4

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


Loading Comments...
%d